Microangiopathic Disorders in Pregnancy

Hematology/Oncology Clinics of North America

Volumn 25, Issue 2, 2011, Pages 311-322

  Pels, Salley G ^a   Paidas, Michael J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HELLP; HUS; Microangiopathic disorders; Preeclampsia; TTP

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTITHROMBIN III; BETAMETHASONE; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4 BINDING PROTEIN; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; CYCLOSPORIN; DEXAMETHASONE; DIPYRIDAMOLE; ECULIZUMAB; FRESH FROZEN PLASMA; GLYCOSPHINGOLIPID; IMMUNOGLOBULIN; INTERLEUKIN 6; INTERLEUKIN 8; MEMBRANE COFACTOR PROTEIN; PLACEBO; PLACENTAL GROWTH FACTOR; RITUXIMAB; SHIGA TOXIN; STEROID; STEROID HORMONE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VINCRISTINE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADRENAL GLAND; ANTIHYPERTENSIVE THERAPY; BRAIN; CAMPYLOBACTER; CANCER THERAPY; CLINICAL FEATURE; CONSERVATIVE TREATMENT; CREATININE BLOOD LEVEL; DIARRHEAGENIC ESCHERICHIA COLI; ENDOTHELIUM LESION; FETUS DISEASE; HEART; HELLP SYNDROME; HEMOLYTIC UREMIC SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; INFLAMMATION; KIDNEY; KIDNEY FAILURE; MATERNAL HYPERTENSION; MATERNAL MORTALITY; MENTAL DISEASE; OVERALL SURVIVAL; PANCREAS; PATHOPHYSIOLOGY; PLASMA TRANSFUSION; PLASMAPHERESIS; POSTPARTUM HEMORRHAGE; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFRACTORY THROMBOCYTOPENIA; REVIEW; SHIGELLA; STEROID THERAPY; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIA; THROMBOCYTOPENIA; THROMBOGENESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; VASCULARIZATION;

ACUTE KIDNEY INJURY; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 79953032397     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.01.005     Document Type: Review

References (69)

1. Baumwell S., Karumanchi S.A. Pre-eclampsia: clinical manifestations and molecular mechanisms. Nephron Clin Pract 2007, 106(2):c72-c81.
2. Kaplan P.W. The neurologic consequences of eclampsia. Neurologist 2001, 7(6):357-363.
3. Terrell D.R., Williams L.A., Vesely S.K., et al. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost 2005, 3:1432-1436.
4. Vesely S.K., George J.N., Lämmle B., et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003, 102(1):60-68.
5. Elliott E.J., Robins-Browne R.M., O'Loughlin E.V., et al. Nationwide study of haemolytic uraemic syndrome: clinical, microbiological, and epidemiological features. Arch Dis Child 2001, 85(2):125-131.
6. Dashe J.S., Ramin S.M., Cunningham F.G. The long-term consequences of thrombotic microangiopathy (thrombotic thrombocytopenic purpura and hemolytic uremic syndrome) in pregnancy. Obstet Gynecol 1998, 91(5 Pt 1):662-668.
7. George J.N. The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2003, 10(5):339-344.
8. Kanasaki K., Kalluri R. The biology of preeclampsia. Kidney Int 2009, 76(8):831-837.
9. Haram K., Svendsen E., Abildgaard U. The HELLP syndrome: clinical issues and management. A review. BMC Pregnancy Childbirth 2009, 9:8.
10. Furlan M., Robles R., Galbusera M., et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998, 339(22):1578-1584.
11. Tsai H.M., Lian E.C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998, 339(22):1585-1594.
12. Levy G.G., Nichols W.C., Lian E.C., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001, 413(6855):488-494.
13. Tsai H.M. Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol 2010, 91(1):1-19.
14. Tsai H.M., Sussman I.I., Nagel R.L. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma. Blood 1994, 83:2171-2179.
15. Schneider S.W., Nuschele S., Wixforth A., et al. Shear-induced unfolding triggers adhesion of von Willebrand factor fibers. Proc Natl Acad Sci U S A 2007, 104(19):7899-7903.
16. Veyradier A., Obert B., Houllier A., et al. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood 2001, 98(6):1765-1772.
17. Sánchez-Luceros A., Farías C.E., Amaral M.M., et al. von Willebrand factor-cleaving protease (ADAMTS13) activity in normal non-pregnant women, pregnant and post-delivery women. Thromb Haemost 2004, 92(6):1320-1326.
18. Mannucci P.M., Canciani M.T., Forza I., et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001, 98(9):2730-2735.
19. Zipfel P.F., Heinen S., Skerka C. Thrombotic microangiopathies: new insights and new challenges. Curr Opin Nephrol Hypertens 2010, 19(4):372-378.
20. Józsi M., Heinen S., Hartmann A., et al. Factor H and atypical hemolytic uremic syndrome: mutations in the C-terminus cause structural changes and defective recognition functions. J Am Soc Nephrol 2006, 17(1):170-177.
21. Fremeaux-Bacchi V., Dragon-Durey M.A., Blouin J., et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004, 41(6):e84.
22. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361(17):1676-1687.
23. Psotka M.A., Obata F., Kolling G.L., et al. Shiga toxin 2 targets the murine renal collecting duct epithelium. Infect Immun 2009, 77(3):959-969.
24. Nolasco L.H., Turner N.A., Bernardo A., et al. Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood 2005, 106(13):4199-4209.
25. Keir L., Coward R.J. Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy. Pediatr Nephrol 2010, [Epub ahead of print].
26. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med 2003, 127(7):834-839.
27. Smulian J., Shen-Schwarz S., Scorza W., et al. A clinicohistopathologic comparison between HELLP syndrome and severe preeclampsia. J Matern Fetal Neonatal Med 2004, 16(5):287-293.
28. Vinnars M.T., Wijnaendts L.C., Westgren M., et al. Severe preeclampsia with and without HELLP differ with regard to placental pathology. Hypertension 2008, 51(5):1295-1299.
29. Banks R.E., Forbes M.A., Searles J., et al. Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1. Mol Hum Reprod 1998, 4(4):377-386.
30. Kappers M.H., van Esch J.H., Sleijfer S., et al. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects. J Hypertens 2009, 27(12):2297-2309.
31. Venkatesha S., Toporsian M., Lam C., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006, 12(6):642-649.
32. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350(7):672-683.
33. Hertig A., Berkane N., Lefevre G., et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem 2004, 50(9):1702-1703.
34. Moore Simas T.A., Crawford S.L., Solitro M.J., et al. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007, 197(3):244. e1-8.
35. Maynard S.E., Moore Simas T.A., Bur L., et al. Soluble endoglin for the prediction of preeclampsia in a high risk cohort. Hypertens Pregnancy 2010, 29(3):330-341.
36. Borzychowski A.M., Sargent I.L., Redman C.W. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med 2006, 11(5):309-316.
37. Grandone E., Tomaiuolo M., Colaizzo D., et al. Role of thrombophilia in adverse obstetric outcomes and their prevention using antithrombotic therapy. Semin Thromb Hemost 2009, 35(7):630-643.
38. Thorp J.M., White G.C., Moake J.L., et al. von Willebrand factor multimeric levels and patterns in patients with severe preeclampsia. Obstet Gynecol 1990, 75(2):163-167.
39. Hulstein J.J., van Runnard Heimel P.J., Franx A., et al. Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. J Thromb Haemost 2006, 4(12):2569-2575.
40. Lattuada A., Rossi E., Calzarossa C., et al. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 2003, 88(9):1029-1034.
41. Martin J.N., Bailey A.P., Rehberg J.F., et al. Thrombotic thrombocytopenic purpura in 166 pregnancies: 1955-2006. Am J Obstet Gynecol 2008, 199(2):98-104.
42. Tsai H.M. Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency. Hematol Oncol Clin North Am 2007, 21(4):609-632.
43. Michael M., Elliott E.J., Ridley G.F., et al. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database Syst Rev 2009, 1. CD003595.
44. Rock G.A., Shumak K.H., Buskard N.A., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991, 325(6):393-397.
45. Henon P. Treatment of thrombotic thrombopenic purpura. Results of a multicenter randomized clinical study. Presse Med 1991, 20(36):1761-1767.
46. Rock G., Anderson D., Clark W., et al. Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet. Br J Haematol 2005, 129(1):79-86.
47. Zeigler Z.R., Shadduck R.K., Gryn J.F., et al. Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP). J Clin Apher 2001, 16(1):19-22.
48. Gunther K. Successful pregnancy despite thrombotic thrombocytopenic purpura in the first trimester. Transfusion 2006, 46(8):1456-1457.
49. Ilter E., Haliloglu B., Temelli F., et al. Thrombotic thrombocytopenic purpura and pregnancy treated with fresh-frozen plasma infusions after plasmapheresis: a case report. Blood Coagul Fibrinolysis 2007, 18(7):689-690.
50. Scully M., Starke R., Lee R., et al. Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura. Blood Coagul Fibrinolysis 2006, 17(6):459-463.
51. Bell W.R., Braine H.G., Ness P.M., et al. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991, 325(6):398-403.
52. Espinoza F., Leal J.L., Arenas G. Successful treatment of thrombotic thrombocytopenic purpura with vincristine report of one case. Rev Med Chil 2007, 135(12):1572-1576.
53. Bobbio-Pallavicini E., Gugliotta L., Centurioni R., et al. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica 1997, 82(4):429-435.
54. Cataland S.R., Jin M., Lin S., et al. Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol 2007, 139(3):486-493.
55. Cataland S.R., Jin M., Lin S., et al. Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura. Am J Hematol 2008, 83(12):911-915.
56. Gutterman L.A., Kloster B., Tsai H.M. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Dis 2002, 28(3):385-391.
57. Elliott M.A., Heit J.A., Pruthi R.K., et al. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. Eur J Haematol 2009, 83(4):365-372.
58. Moore J.C., Arnold D.M., Leber B.F., et al. Intravenous immunoglobulin as an adjunct to plasma exchange for the treatment of chronic thrombotic thrombocytopenic purpura. Vox Sang 2007, 93(2):173-175.
59. Rizzoni G., Claris-Appiani A., Edefonti A., et al. Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr 1988, 112(2):284-290.
60. Loirat C., Sonsino E., Hinglais N., et al. Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr Nephrol 1988, 2(3):279-285.
61. Sánchez-Corral P., Melgosa M. Advances in understanding the aetiology of atypical Haemolytic Uraemic Syndrome. Br J Haematol 2010, 150(5):529-542.
62. Ariceta G., Besbas N., Johnson S., et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009, 24(4):687-696.
63. Köse O., Zimmerhackl L.B., Jungraithmayr T., et al. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Semin Thromb Hemost 2010, 36(6):669-672.
64. Marasca R., Coluccio V., Santachiara R., et al. Pregnancy in PNH: another eculizumab baby. Br J Haematol 2010, 150(6):707-708.
65. Perez N., Spizzirri F., Rahman R., et al. Steroids in the hemolytic uremic syndrome. Pediatr Nephrol 1998, 12(2):101-104.
66. Woudstra D.M., Chandra S., Hofmeyr G.J., et al. Corticosteroids for HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome in pregnancy. Cochrane Database Syst Rev 2010, 9. CD008148.
67. Martin J.N., Perry K.G., Roberts W.E., et al. Plasma exchange for preeclampsia: II. Unsuccessful antepartum utilization for severe preeclampsia with or without HELLP syndrome. J Clin Apher 1994, 9(3):155-161.
68. Mangione S., Giarratano A. The role of antithrombin III in critical patients in obstetrics. Minerva Anestesiol 2002, 68(5):449-453.
69. Maki M., Kobayashi T., Terao T., et al. Antithrombin therapy for severe pre-eclampsia: result of a double-blind, randomized, placebo-controlled trial. Thromb Haemost 2000, 84:583-590.